PRIMARY STUDY
Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death
Key Findings: TRPV1 (and potentially CB2) antagonism via NADA for example may present novel treatment potential for patients with immune dysfunction in end-stage kidney disease.
Type of Study: Laboratory Study
Study Result: Positive
Research Location(s): Australia
Year of Pub: 2009
Cannabinoids Studied: N-Arachidonoyl Dopamine (NADA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB2, TRPV1
Route of Administration: In vitro
Citation: Saunders CI, et al. Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death. Biochim Biophys Acta. 2009; 1792:1019-26. doi: 10.1016/j.bbadis.2009.07.008
Authors: Saunders CI, Fassett RG, Geraghty DP
